Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
136.38
-1.36 (-0.99%)
Dec 20, 2024, 4:00 PM EST - Market closed
Ascendis Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 327.43 | 266.72 | 51.17 | 7.78 | 6.95 | 13.38 | Upgrade
|
| Revenue Growth (YoY) | 115.54% | 421.20% | 557.93% | 11.87% | -48.01% | 26.41% | Upgrade
|
| Cost of Revenue | 49.69 | 44.4 | 12.14 | 3.52 | - | - | Upgrade
|
| Gross Profit | 277.74 | 222.32 | 39.04 | 4.26 | 6.95 | 13.38 | Upgrade
|
| Selling, General & Admin | 274.9 | 264.41 | 221.23 | 160.18 | 76.67 | 48.47 | Upgrade
|
| Research & Development | 318.59 | 413.45 | 379.62 | 295.87 | 260.9 | 191.62 | Upgrade
|
| Operating Expenses | 593.49 | 677.86 | 600.85 | 456.05 | 337.57 | 240.09 | Upgrade
|
| Operating Income | -315.76 | -455.54 | -561.81 | -451.79 | -330.62 | -226.72 | Upgrade
|
| Interest Expense | -109.78 | -44.07 | -30.68 | -3.91 | -1.92 | -1.22 | Upgrade
|
| Interest & Investment Income | - | 16.86 | 7.43 | 0.69 | 1.81 | 10.06 | Upgrade
|
| Earnings From Equity Investments | -18.41 | -18.4 | -17.7 | 12.04 | -9.52 | -8.11 | Upgrade
|
| Currency Exchange Gain (Loss) | 12.35 | 12.35 | 40.43 | 59.03 | -78.92 | 7.75 | Upgrade
|
| Other Non Operating Income (Expenses) | 14.65 | 14.65 | -15.48 | - | - | - | Upgrade
|
| Pretax Income | -416.95 | -474.14 | -577.82 | -383.94 | -419.17 | -218.25 | Upgrade
|
| Income Tax Expense | 9.55 | 7.3 | 5.38 | -0.37 | -0.22 | -0.23 | Upgrade
|
| Net Income | -426.49 | -481.45 | -583.19 | -383.58 | -418.96 | -218.02 | Upgrade
|
| Net Income to Common | -426.49 | -481.45 | -583.19 | -383.58 | -418.96 | -218.02 | Upgrade
|
| Shares Outstanding (Basic) | 57 | 56 | 56 | 55 | 51 | 47 | Upgrade
|
| Shares Outstanding (Diluted) | 57 | 56 | 56 | 55 | 51 | 47 | Upgrade
|
| Shares Change (YoY) | 1.70% | 0.38% | 2.37% | 8.21% | 8.84% | 13.20% | Upgrade
|
| EPS (Basic) | -7.47 | -8.55 | -10.40 | -7.00 | -8.28 | -4.69 | Upgrade
|
| EPS (Diluted) | -7.47 | -8.55 | -10.40 | -7.00 | -8.28 | -4.69 | Upgrade
|
| Free Cash Flow | -262.44 | -469.8 | -510.19 | -441.35 | -291.41 | -181.1 | Upgrade
|
| Free Cash Flow Per Share | -4.60 | -8.35 | -9.10 | -8.06 | -5.76 | -3.89 | Upgrade
|
| Gross Margin | 84.82% | 83.36% | 76.28% | 54.71% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -96.44% | -170.79% | -1097.85% | -5808.59% | -4755.07% | -1695.10% | Upgrade
|
| Profit Margin | -130.26% | -180.51% | -1139.63% | -4931.56% | -6025.53% | -1630.03% | Upgrade
|
| Free Cash Flow Margin | -80.15% | -176.14% | -996.97% | -5674.38% | -4191.11% | -1353.98% | Upgrade
|
| EBITDA | -309.9 | -448.99 | -556.04 | -436.85 | -321.17 | -225.27 | Upgrade
|
| EBITDA Margin | -94.65% | -168.34% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 5.86 | 6.55 | 5.77 | 14.95 | 9.45 | 1.45 | Upgrade
|
| EBIT | -315.76 | -455.54 | -561.81 | -451.79 | -330.62 | -226.72 | Upgrade
|
| EBIT Margin | -96.44% | -170.79% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.